FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells
Leukemia ( IF 12.8 ) Pub Date : 2024-07-16 , DOI: 10.1038/s41375-024-02345-0
Anna Sperk _{1,

2} , Antje Gabriel _{1,

2} , Daniela Koch _{1,

2} , Abirami Augsburger _{1,

2} , Victoria Sanchez ₃ , David Brockelt _{1,

2} , Rupert Öllinger _{2,

4} , Thomas Engleitner _{2,

5} , Piero Giansanti _{2,

6} , Romina Ludwig ₇ , Priska Auf der Maur _{1,

2} , Wencke Walter ₈ , Torsten Haferlach ₈ , Irmela Jeremias _{7,

9} , Roland Rad _{2,

4,

5} , Barbara Steigenberger ₃ , Bernhard Kuster _{10,

11,

12} , Ruth Eichner _{1,

2} , Florian Bassermann _{1,

2,

11,

12}

Affiliation

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Mass Spectrometry Core Facility, Max Planck Institute of Biochemistry, Martinsried, Germany.
Medical Department II, Translational Gastroenterological Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Molecular Oncology and Functional Genomics, Technical University of Munich, Munich, Germany.
Bavarian Center for Biomolecular Mass Spectrometry at the University Hospital rechts der Isar Technical University of Munich, Munich, Germany.
Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, Munich, Germany.
MLL Munich Leukemia Laboratory, Munich, Germany.
Department of Pediatrics, Dr. Von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Munich, Germany.
Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.
Deutsches Konsortium fürr Translationale Krebsforschung (DKTK), Heidelberg, Germany.
Bavarian Cancer Research Center (BZKF), Munich, Germany.